论文部分内容阅读
探讨鼠类双微体２ 癌基因（ＭＤＭ２）、Ｐ５３ 蛋白在星形细胞瘤中的表达与肿瘤病理分级和预后之间的关系。以免疫组化ＳＡＢＣ法检测３６ 例确诊并有随访的星形细胞瘤中ＭＤＭ２ 和Ｐ５３ 蛋白。结果表明：ＭＤＭ２及Ｐ５３ 蛋白阳性表达率分别为４４．４％ （１６／３６ 例）和３８．９％ （１４／３６ 例），其阳性率与患者年龄、性别无关，但与肿瘤病理分级呈显著正相关（分别为Ｐ＜ ０．０５，Ｐ＜ ０．０１）。３６ 例星形细胞瘤中ＭＤＭ２ 和Ｐ５３ 共同阳性表达９ 例（２５％ ），这９ 例与ＭＤＭ２ 和Ｐ５３ 蛋白表达均阴性病例的１ 年和３ 年存活率之间差异显著（Ｐ＜ ０．０５）。提示ＭＤＭ２ 和Ｐ５３蛋白阳性检出率有助于判断星形细胞瘤恶性程度及预测肿瘤预后
To investigate the relationship between the expression of MDM2 and P53 protein in astrocytoma and the pathological grade and prognosis of the tumor. The immunohistochemical SABC method was used to detect MDM2 and P53 protein in 36 astrocytomas diagnosed and followed up. The results showed that the positive expression rates of MDM2 and P53 protein were 44.4% (16/36 cases) and 38.9% (14/36 cases) respectively. The positive rate of MDM2 and P53 protein was not related to the age and gender of the patients, but it was consistent with the pathological grade of tumors. Significantly positive correlations (P < 0.05, P <0.01, respectively). In 36 cases of astrocytoma, 9 cases (25%) of MDM2 and P53 were positively expressed. There was a significant difference between the 1 and 3 year survival rates of these 9 cases and MDM2 and P53 protein negative cases (P<0.05). ). It is suggested that the positive detection rate of MDM2 and P53 protein can help determine the malignancy of astrocytoma and predict the prognosis of astrocytoma.